CR Pharma Completes RMB1.50 Billion First-Tranche Issuance of 2026 Corporate Bonds at 1.65% Coupon

Bulletin Express

Apr 16

China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the first tranche of 2026 corporate bonds in mainland China.

The tranche raised RMB1.50 billion with a three-year tenor and an annual coupon rate of 1.65%. The offering forms part of a China Securities Regulatory Commission–approved programme allowing CR Pharmaceutical Holdings to issue up to RMB10 billion in corporate bonds to qualified PRC investors (CSRC approval Zheng Jian Xu Ke [2025] No. 1457).

Net proceeds will be allocated to production expenditures, repayment of corporate debt, replenishment of working capital, project development and operating costs, as well as investments in scientific and technological innovation, in accordance with relevant regulations.

The company reiterated that shareholders and prospective investors should exercise caution when dealing in its securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1105924645"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105924645\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105924645?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-16 19:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105924645","market":"hk","top_or_hot":-1,"title":"CR Pharma Completes RMB1.50 Billion First-Tranche Issuance of 2026 Corporate Bonds at 1.65% Coupon","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the first tranche of 2026 corporate bonds in mainland China.</p>\n<p>The tranche raised RMB1.50 billion with a three-year tenor and an annual coupon rate of 1.65%. The offering forms part of a China Securities Regulatory Commission–approved programme allowing CR Pharmaceutical Holdings to issue up to RMB10 billion in corporate bonds to qualified PRC investors (CSRC approval Zheng Jian Xu Ke [2025] No. 1457).</p>\n<p>Net proceeds will be allocated to production expenditures, repayment of corporate debt, replenishment of working capital, project development and operating costs, as well as investments in scientific and technological innovation, in accordance with relevant regulations.</p>\n<p>The company reiterated that shareholders and prospective investors should exercise caution when dealing in its securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Pharma Completes RMB1.50 Billion First-Tranche Issuance of 2026 Corporate Bonds at 1.65% Coupon</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Pharma Completes RMB1.50 Billion First-Tranche Issuance of 2026 Corporate Bonds at 1.65% Coupon\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-16 19:43</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the first tranche of 2026 corporate bonds in mainland China.</p>\n<p>The tranche raised RMB1.50 billion with a three-year tenor and an annual coupon rate of 1.65%. The offering forms part of a China Securities Regulatory Commission–approved programme allowing CR Pharmaceutical Holdings to issue up to RMB10 billion in corporate bonds to qualified PRC investors (CSRC approval Zheng Jian Xu Ke [2025] No. 1457).</p>\n<p>Net proceeds will be allocated to production expenditures, repayment of corporate debt, replenishment of working capital, project development and operating costs, as well as investments in scientific and technological innovation, in accordance with relevant regulations.</p>\n<p>The company reiterated that shareholders and prospective investors should exercise caution when dealing in its securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1105924645","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105924645","pubTimestamp":1776339839,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"华润医药完成2026年第一期15亿元公司债券发行，票面利率1.65%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Limited (abbreviated as CR Pharma) announced that its wholly-owned subsidiary, China Resources Pharmaceutical Holdings Company Limited, has completed the public issuance of the first tranche of 2026 corporate bonds in mainland China.\nThe tranche raised RMB1.50 billion with a three-year tenor and an annual coupon rate of 1.65%. The offering forms part of a China Securities Regulatory Commission–approved programme allowing CR Pharmaceutical Holdings to issue up to RMB10 billion in corporate bonds to qualified PRC investors (CSRC approval Zheng Jian Xu Ke [2025] No. 1457).\nNet proceeds will be allocated to production expenditures, repayment of corporate debt, replenishment of working capital, project development and operating costs, as well as investments in scientific and technological innovation, in accordance with relevant regulations.\nThe company reiterated that shareholders and prospective investors should exercise caution when dealing in its securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}